仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 （Ang-2） from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects